Locoregional IL-2 low dose applications for gastrointestinal tumors

World Journal of Gastroenterology

Volumn 11, Issue 35, 2005, Pages 5525-5529

  Krastev, Zachary ^a   Koltchakov, V ^a   Tomova, R ^a   Deredjian, S ^a   Alexiev, A ^a   Popov, D ^a   Tomov, B ^a   Koten, Jan Willem ^b   Jacobs, John ^b   Den Otter, Willem ^b  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^b Faculty of Veterinary Medicine   (Netherlands)

Author keywords

Gastrointestinal cancer; Interleukin 2; Local IL 2 therapy

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT INTERLEUKIN 2;

ABDOMINAL CANCER; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROENTEROLOGY; GASTROINTESTINAL TUMOR; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HUMAN; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MALE; METHODOLOGY; NAUSEA; TREATMENT OUTCOME; VOMITING;

EID: 28044433404     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i35.5525     Document Type: Article

References (20)

1. Maas RA, Dullens HF, De Jong WH, Den Otter W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res 1989; 49(24 Pt 1): 7037-7040
2. Kusnierczyk H, Pajtasz Piasecka E, Koten JW, Bijleveld C, Krawczyk K, Den Otter W. Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 2004; 53: 445-452
3. Balemans LTM, Mattijssen V, Steerenberg PA, Van Driel BE, De Mulder PHM, Den Otter W. Locoregional therapy with polyethyleneglycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pigs induces T-cell-mediated antitumour activity. Cancer Immunol Immunother 1993; 37: 7
4. Den Otter W, Hill FW, Klein WR, Koten JW, Steerenberg PA, De Mulder PH, Rutten VP, Ruitenberg EJ. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 1993; 13: 2453-2455
5. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Faber JAJ, Ruitenberg EJ, Rutten VPMG Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 mo of follow-up. Cancer Immunol Immunother 1995; 41: 10
6. Spoormakers TJ, Klein WR, Jacobs JJ, Van Den Ingh TS, Koten JW, Den Otter W. Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or Cisplatin/IL-2. Cancer Immunol Immunother 2003; 52: 179-184
7. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 out of 10 patients. J Urol 1998; 159: 1183
8. Pizza G, Severini G, Menniti D, De Vinci C, Corrado F. Tumor regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Int J Cancer 1984; 34: 359-367
9. Jacobs JJ, Hordijk GJ, Jurgenliemk-Schulz IM, Terhaard CH, Koten JW, Battermann JJ, Den Otter W. Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low dose of IL-2. Cancer Immunol Immunother 2005; 54: 792-798
10. Huland E, Heinzer H, Huland H. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res 1999; 19: 2679
11. Den Otter W, De Groot JW, Bernsen MR, Heintz APM, Maas R, Hordijk GJ, Hill FWG, Klein WR, Ruitenberg EJ, Rutten VPMG. Optimal regimes for local IL-2 tumour therapy. Int J Cancer 1996; 88: 400
12. Baselmans AHC, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 2002; 51: 492
13. Jacobs JJ, Sparendam D, Den Otter W. Local Interleukin-2 therapy is therapeutically most effective against cancer when injected intratumorally. Cancer Immunol Immunother 2005; 54: 647-654
14. Balemans LTM, Steerenberg PA, Koppenhagen FJ, Kremer BRA, De Mulder PHM, Claessen AME, Scheper RJ, Den Otter W. PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumour and beneficial effect of cyclophosphamide. Int J Cancer 1994; 58: 871
15. Van Es RJJ, Baselmans AHC, Van Dijk JE, Koole R, Den Otter W. Perilesional IL-2 treatment of a VX2 head and neck cancer model can induce a systemic antitumor activity. Anticancer Res 2000; 20: 4163
16. Krastev Z, Koltchakov V, Popov D, Alexiev A, Koten JW, Den Otter W. A case of hepatocellular carcinoma (HCC): Treatment with local application of alcohol and interleukin-2 (IL-2). Hepatogastroenterology 2003; 50: 1647
17. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W. A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 2001; 50: 226
18. Bernsen MR, Van der Velden D, Everse LA, Dullens HFJ, Den Otter W, Heintz APM. Interleukin-2: Hope in case of Cisplatin resistant tumors. Cancer Immunol Immunother 1998; 46: 41
19. Everse LA, Renes IB, Jürgenliempk-Schultz IM, Rutgers DH, Bernsen MR, Dullens HFJ, Den Otter W, Battermann JJ. Local low dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A preclinical study. Int J Cancer 1997; 72: 1003
20. Lissoni P, Mandala M, Curigliano G, Ferretti G, Moro C, Arddizoia A, Malugani F, Tancini G, Tisi E, Arrigoni C, Barni S. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin 2. Oncology 2001; 60: 308